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Amlodipine Reduces AngII-Induced Aortic Aneurysms
and Atherosclerosis in Hypercholesterolemic Mice
Xiaofeng Chen1, Debra L. Rateri1, Deborah A. Howatt1, Anju Balakrishnan1, Jessica J. Moorleghen1,
Andrew J. Morris1, Richard Charnigo2, Lisa A. Cassis3, Alan Daugherty1*
1 Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America, 2 Department of Biostatistics, University of
Kentucky, Lexington, Kentucky, United States of America, 3 Department of Molecular and Biochemical Pharmacology, University of Kentucky, Lexington,
Kentucky, United States of America
Abstract
Background: The purpose of this study was to determine effects of amlodipine, a dihydropyridine calcium channel
blocker, on development of angiotensin II (AngII)-induced vascular pathologies.
Methods and Results: Male LDL receptor -/- mice were infused with vehicle, amlodipine (5 mg/kg/d), AngII (1,000
ng/kg/min), or AngII + amlodipine for 4 weeks through osmotic pumps (n=10/group). Mice were fed a saturated fat-
enriched diet for 1 week prior to pump implantation and during 4 weeks of infusion. Infusion of amlodipine resulted in
plasma concentrations of 32 ± 2 ng/ml and 27 ± 2 ng/ml for mice in saline + amlodipine and AngII + amlodipine
groups, respectively. This infusion rate of amlodipine did not affect AngII-induced increases in systolic blood
pressure. Three of 10 (30%) mice infused with AngII died of aortic rupture, while aortic rupture did not occur in mice
co-infused with AngII + amlodipine. Suprarenal aortic width and intimal area of ascending aortas were measured to
define aortic aneurysms. In the absence of AngII infusion, amlodipine did not change suprarenal aortic width and
ascending aortic area. Infusion of AngII led to profound increases of suprarenal aortic width (saline + vehicle versus
AngII + vehicle: 0.86 ± 0.02 versus 1.72 ± 0.26 mm; P=0.0006), whereas co-infusion of AngII and amlodipine
diminished abdominal dilation (1.02 ± 0.14 mm; P=0.003). As expected, AngII infusion increased mean intimal area
of ascending aortas (saline + vehicle versus AngII + vehicle: 8.5 ± 0.3 versus 12.5 ± 1.1 mm2; P=0.001), while co-
infusion of AngII and amlodipine ablated dilation of the ascending aorta (8.6 ± 0.2 mm2; P=0.03). Co-administration of
amlodipine also significantly attenuated AngII-induced atherosclerosis in the thoracic region as quantified by percent
lesion area (AngII + vehicle versus AngII + amlodipine: 5.8 ± 2.1 % versus 0.3 ± 0.1%; P=0.05).
Conclusions: Amlodipine inhibited AngII-induced aortic aneurysms in both the abdominal and ascending regions,
and atherosclerosis in hypercholesterolemic mice.
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Introduction
Aortic aneurysmal and atherosclerotic diseases may occur
coincidently in humans [1-5]. Excessive stimulation of the renin
angiotensin system (RAS) has been implicated in many human
cardiovascular diseases, including aortic aneurysms and
atherosclerosis [6,7]. There are substantial experimental data
that excessive RAS activation also promotes these diseases in
animal models. AngII infusion into LDL receptor -/-, apoE -/- or
normolipidemic mice induces development of aneurysms in the
suprarenal region of the abdominal aorta [8-11]. More recently,
it has been noted that AngII infusion also promotes pronounced
dilation of the thoracic aorta, which is restricted to the
ascending region [12,13]. In addition to promoting formation of
aortic aneurysms, many studies have reported that chronic
subcutaneous infusion of AngII into mice augments
development of atherosclerosis in both apoE -/- and LDL
receptor -/- mice [8,9,14].
Since AngII infusion into hypercholesterolemic mice
promotes diverse aortic pathologies, this model permits
simultaneous determination of effects of an intervention on
abdominal and thoracic aortic aneurysms as well as
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atherosclerosis. Several studies have demonstrated that
interventions can have differential effects on abdominal aortic
aneurysms and atherosclerosis. These include
pharmacological interventions with doxycycline, bosentan, and
pioglitazone [15-17], and surgical interventions such as
orchidectomy [18]. Genetic manipulations have also provided
divergent effects including whole body genetic deletion of
interferon-gamma, CXCL10, receptor-associated protein, or
Rag-1 [19-21], and cell-specific deletion of PPAR gamma or
AT1a receptors [17,22]. In contrast, several interventions have
similar effects on these pathologies including pharmacological
inhibition or whole body genetic deficiency of AT1a receptor
[23,24], an AT2 receptor antagonist [23] and whole body
deficiency of CCR2 [12]. Whole body deficiency of AT1a
receptor or CCR2 also decreased AngII-induced thoracic aortic
aneurysms [12,22]. Findings from these studies implicate that
the aortic pathologies in aneurysms and atherosclerosis may
be attributed to a combination of common and distinctive
mechanisms.
Anti-hypertensive drugs, including calcium channel blockers,
are commonly prescribed for hypertensive patients who
frequently also have aortic aneurysmal or atherosclerotic
diseases. Although one study indicates that this class of drugs
may have detrimental effects on abdominal aortic aneurysms in
humans [25], calcium channel blockade has been shown to
decrease atherosclerosis in humans [25-30]. However, this has
not been determined in prospective studies. The purpose of
this study was to determine effects of a commonly used
calcium channel blocker, amlodipine, on aortic pathologies in a
mouse model that develops aortic aneurysms and
atherosclerosis simultaneously.
Materials and Methods
Ethics Statement
Recommendations from the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health) were
followed. All procedures were approved by the University of
Kentucky Institutional Animal Care and Use Committee
(Protocol # 2006-0009). Mice were examined daily for signs of
distress, dehydration, lack of weight gain, or bilateral hind leg
paralysis. No adverse effects were noted during this study.
Mice were terminated by overdose of a ketamine/xylazine
mixture.
Mice
Male low-density lipoprotein (LDL) receptor -/- mice (stock #
002207; > N10 background into the C57BL/6 background) were
purchased from the Jackson Laboratory (Bar Harbor, ME,
USA). Mice were housed in individually ventilated cages with
negative air pressure (Allentown Inc; Allentown, NJ, USA).
Filtered drinking water by reverse osmosis system was
provided ad libitum. Normal mouse diet (Global 18% protein
rodent diet; Diet # 2918; Harlan Teklad; Madison, WI, USA)
was fed. Light and dark cycle of the room was 14 hours of light
and 10 hours of dark. Ambient temperature ranged from 20 to
23°C and humidity was 50-60%. Necropsy was performed on
mice that died during AngII infusions within 12 hours of
expiration. Systolic blood pressure was measured by a tail cuff
based technique using Coda 8 machines (Kent Scientific,
Torrington, CT, USA) as described previously [31].
Diet and Drug Administration
To induce hypercholesterolemia, mice were fed a diet
enriched in saturated fat (milk fat 21% wt/wt) and 0.2% wt/wt
cholesterol (Diet # TD.88137; Harlan Teklad) 1 week prior to
osmotic mini-pump implantation and throughout the 4 weeks of
infusions.
Four groups (n=10 per group) of mice were infused with: 1.
saline + vehicle [50% dimethyl sulfoxide (DMSO)]; 2. saline +
amlodipine (5 mg/kg/day); 3. AngII (1,000 ng/kg/min) + vehicle
(50% DMSO); and 4. AngII + amlodipine. For osmotic pump
preparation (Durect Corporation; Cupertino, CA, USA), AngII
(1,000 ng/kg/min; Cat # H-1705; Bachem; Torrance, CA, USA)
was dissolved in saline. AngII and saline were infused using
Alzet model 1004. Amlodipine besylate (5 mg/kg/day; Cat #
A5605; Sigma-Aldrich; St. Louis, MO, USA) was dissolved in
50% DMSO. Amlodipine and vehicle (50% DMSO) were
infused using Alzet model 2004. After anesthesia with
ketamine/xylazine (90 and 10 mg/kg body weight, respectively),
a Model 1004 pump and a Model 2004 pump were implanted
subcutaneously into the flanks of each mouse [9]. A topical
analgesic, LMX4 (Ferndale Laboratories; Ferndale, MI, USA),
was used to provide relief from pain associated with surgery.
Plasma Measurements
Plasma cholesterol concentrations were measured using a
commercially available enzymatic kit (Cat # Cholesterol E
439-17501; Wako Chemicals; Richmond, VA, USA) as
described previously [32]. Plasma lipoprotein fractions were
resolved by size exclusion chromatography and cholesterol
concentrations were measured using the cholesterol enzymatic
kit as described previously [32].
Plasma amlodipine concentrations were measured by HPLC
electrospray ionization tandem mass spectrometry using
adaptation of a previously reported method [33]. Briefly,
individual plasma samples (50 μl) were extracted with ethyl
ether: dichloromethane (70:30). After centrifugation, the
supernatant was evaporated to dryness. Dried samples were
reconstituted in a mixture of ammonium formate/ methanol/
acetonitrile (30:50:20; 50 µl). Samples (10 μl) were analyzed
using a Shimadzu automated HPLC system with an Agilent
Eclipse XDB C18 column (Agilent; Santa Clara, CA, USA)
coupled with an AB Sciex 4000-Qtrap hybrid linear ion trap
triple quadrupole mass spectrometer (AB Sciex; Framingham,
MA, USA) that was operated in multiple reaction monitoring
mode. Tizanidine (Cat # T6950; Sigma Aldrich) was used as an
internal standard. Quantitation was accomplished by reference
to an offline calibration generated using amlodipine that was
independently quantitated by accurate mass measurements.
Plasma renin concentrations were measured as described
previously [34]. Briefly, individual plasma samples (8 μl)
harvested with EDTA (1.8 mg/ml) were incubated with an
excess of rat angiotensinogen at 37 °C for 30 minutes. The
generated AngI was quantified by radioimmunoassay using a
Amlodipine Attenuates Aortic Aneurysms
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commercially available kit (Cat # 1553; DiaSorin; Stillwater,
MN, USA).
Quantification of Aortic Aneurysms and
Atherosclerosis
Aortas were dissected from the root to iliac bifurcation and
placed in 10% neutrally buffered formalin overnight. After
removal of adventitia, aortas were pinned and photographed.
Maximal ex vivo diameters of suprarenal aortas were
measured with ImagePro Plus software (Media Cybernetics;
Rockville, MD, USA) to quantitate AAAs [11,35]. Subsequently,
aortas were cut open longitudinally, secured with pins, and
photographed. To determine formation of thoracic aortic
aneurysms, dilation of ascending aortas was quantified by
measurement of intimal area of the ascending aortic region
[12]. Atherosclerosis was quantified on the intimal surface of
the aorta by an en face technique as described previously
[36,37].
Histological and Immunohistochemical Staining
Aortic tissues were fixed with 4% paraformaldehyde, and
then sectioned on a cryostat at a thickness of 10 µm. Sections
were histologically stained using Verhoeff’s hematoxylin to
visualize the integrity of elastin. Immunohistochemical staining
was performed as described previously [38]. Smooth muscle
cells were detected using smooth muscle α-actin antibody (2
μg/ml; Abcam, cat# ab5694) and macrophages using an CD68
antibody (5 μg/ml; Serotec, cat# MCA1957GA). Positively
reactive areas were visualized via application of an ABC kit
(Vector) and subsequent detection with AEC chromogen
(Vector). Images were captured using a Nikon Eclipse E600
scope and a Nikon DXM1200F digital camera.
Statistical Analyses
Data for continuous variables are summarized as means ±
standard error of means (SEM). Version 9.2 of SAS (SAS
Institute, Cary NC) was used for data analysis (SAS Institute
Inc.; Cary, NC, USA). Effects of AngII and amlodipine were
assessed by two-way analysis of variance (ANOVA) if
normality and equal variance assumptions were satisfied (or if
violations of these assumptions could be addressed by
transforming the data or reweighting the observations) and
were assessed posthoc by nonparametric Kruskal-Wallis test
otherwise. P≤0.05 was considered significantly different.
Results
Characteristics of Study Mice
Amlodipine was infused subcutaneously through osmotic
pumps to maintain a constant plasma concentration throughout
the study. Plasma concentrations of amlodipine were not
significantly different between the groups that were co-infused
with either saline or AngII (32 ± 2 ng/ml and 27 ± 2 ng/ml,
respectively), while the drug was not detectable in saline +
vehicle or AngII + vehicle infused mice (Figure 1). Amlodipine
administration had no effect on body weight, plasma
cholesterol concentrations, and plasma lipoprotein-cholesterol
distributions in mice infused with either saline or AngII (Table
1). Amlodipine also had no significant effect on systolic blood
pressure in mice infused with AngII (150 ± 3 versus 148 ± 4
mmHg for AngII + vehicle versus AngII + amlodipine-infused
mice, respectively). AngII infusion significantly decreased
plasma renin concentration (P=0.005); however, addition of
amlodipine significantly increased plasma renin concentration
(P<0.0001; Table 1).
Figure 1.  Plasma concentrations of amlodipine.  Plasma concentrations of amlodipine were measured at the end of study.
Circles and triangles represent individual mice, diamonds are means of groups, and error bars are SEMs. * denotes P<0.0001
comparing amlodipine groups with saline + vehicle and AngII + vehicle groups by two way ANOVA.
doi: 10.1371/journal.pone.0081743.g001
Amlodipine Attenuates Aortic Aneurysms
PLOS ONE | www.plosone.org 3 November 2013 | Volume 8 | Issue 11 | e81743
Amlodipine Prevented Development of AngII-induced
Aneurysms in Both Abdominal and Ascending Aortic
Regions
Three of 10 mice infused with AngII died of aortic rupture
within 10 days after initiating AngII infusion, while no aortic
ruptures occurred in the other 3 groups as shown in Figure 2.
To determine effects of amlodipine on development of AAAs,
maximal diameters of suprarenal aortas were measured ex
vivo. Amlodipine had no effect on suprarenal aortic width in
saline-infused mice. As described previously, infusion of AngII
led to profound increases of maximal aortic width (saline +
vehicle versus AngII + vehicle: 0.86 ± 0.02 versus 1.72 ± 0.26
mm; P=0.0006). Amlodipine administration significantly
attenuated AngII-induced abdominal aortic dilation (1.02 ± 0.14
mm; P=0.003; Figure 3). Aortas from AngII-infused mice
administered with amlodipine were grossly normal as
demonstrated by histological analysis (Figure 4). To determine
Table 1. Characteristics of study mice.
Infusions Saline  AngII  
 Vehicle Amlodipine Vehicle Amlodipine
n 10 10 7* 10
Body weight (g) 28.0 ± 0.5 27.6 ± 0.5 26.9 ± 0.6 26.9 ± 0.5
Plasma cholesterol (mg/dl) 1038 ± 41 949 ± 41 1168 ± 49 1119 ± 41
Plasma renin (ng/ml/30 min) 3.0 ± 0.3 8.5 ± 1.3† 1.1 ± 0.1# 5.2 ± 1.1†#
Body weight, plasma cholesterol and renin concentrations were measured after 28
days of infusions. Values are represented as mean ± SEM. * Ten mice were
initiated in the study, but 3 succumbed to aortic rupture, so data were derived from
7 surviving mice. † P<0.0001, compared to vehicle within saline or AngII groups. #
P=0.005, compared to saline infusion within vehicle or amlodipine groups.
doi: 10.1371/journal.pone.0081743.t001
whether any pathological changes were discernible, aortic
tissues were sectioned and immunohistochemically and
histologically stained. As the example shown in Figure 4,
suprarenal aortas from amlodipine infused mice were grossly
normal with consistent smooth muscle α-actin immunostaining,
intact elastin fibers in the media, and no accumulation of
macrophages.
En face measurement of intimal surface area of the
ascending aorta was used as an index to determine ascending
aortic dilation [12]. Administration of amlodipine had no effect
on ascending aortic area in saline-infused mice. AngII infusion
significantly increased mean intimal area of ascending aortas
(saline + vehicle versus AngII + vehicle: 8.5 ± 0.3 versus 12.5 ±
1.1 mm2; P=0.001). Co-infusion of AngII with amlodipine
ablated AngII-induced ascending aortic dilation (8.6 ± 0.2 mm2;
P=0.03; Figure 5). As with the suprarenal aorta, infusion of
amlodipine led to preservation of a normal histological
appearance of the ascending aorta (Figure 4).
Amlodipine Reduced Atherosclerosis in AngII-infused
Hypercholesterolemic Mice
Atherosclerotic lesion size was only minor in mice infused
with saline + vehicle and saline + amlodipine after 5 weeks of
feeding the saturated fat-enriched diet. Consistent with
previous studies [9,39], mice infused with AngII had
significantly increased lesion area in the thoracic aorta (saline +
vehicle versus AngII + vehicle: 0.22 ± 0.18 % versus 5.76 ±
2.29 %; P=0.02; Figure 6). Co-infusion of amlodipine reduced
atherosclerosis in AngII-infused mice (0.27 ± 0.14 %; P=0.05).
Discussion
AngII infusion simultaneously induces aneurysms in the
suprarenal and ascending regions of the aorta and augments
Figure 2.  Survival curve for study mice.  The survival curve for the four groups of mice during the infusion interval. Mice infused
with AngII + vehicle had 3 deaths (occurred on days 3, 4, and 8) due to aortic rupture, while no deaths occurred in the other groups.
doi: 10.1371/journal.pone.0081743.g002
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atherosclerosis in hypercholesterolemic mice, as demonstrated
in the present and previous studies [9,12,14,40]. Despite
markedly different vascular pathologies promoted by chronic
AngII infusion, the present study provides evidence that
continuous infusion of a dihydropyridine calcium channel
blocker, amlodipine, has pronounced effects on inhibition of
these diverse pathologies that developed in mice rendered
hypercholesterolemia by deletion of LDL receptor and feeding
a diet that has a high saturated fat content (42% by calories),
compared to normal laboratory diet (18% fat by calories).
Amlodipine has commonly been administrated by gavage,
mixed with diet, or dissolved in drinking water [41-46]. In the
present study, amlodipine was given using osmotic minipumps,
as used in a previous study [47]. This approach was used to
provide stable calcium channel blockade throughout the 28
days of AngII infusion. In addition to providing a mode of
constant drug delivery, we also measured plasma
concentrations of this drug in mouse plasma. The detected
concentrations (mean concentration of saline + amlodipine and
AngII + amlodipine: 29.3 ± 1.7 ng/ml) are above the reported
EC50 of amlodipine [48,49]. By comparison to humans, a
single dose of 10 mg amlodipine to healthy male volunteers
resulted in plasma concentrations of 5.9 ± 1.2 ng/ml. Repeated
daily dosing led to mean plasma concentrations of 14.5 ± 5.8
ng/ml with peaks and troughs of 18.1 ± 7.1 and 11.8 ± 5.3
ng/ml, respectively [50,51]. Therefore, plasma concentrations
of amlodipine achieved in this mouse study were in a similar
range to those achieved in humans.
Previous studies have demonstrated that increased systolic
blood pressure observed during AngII infusion is not the
determinant of aortic aneurysmal formation or atherosclerosis
augmentation [14,40,52,53]. In agreement with these previous
reports, the present study also found that amlodipine reduced
all vascular pathologies without resulting in any measurable
change in systolic blood pressure. This result extends the
findings by Kanematsu et al. [54], who reported that amlodipine
reduced both systolic blood pressure and aortic aneurysmal
formation in normocholesterolemic mice.
We also found that amlodipine administration increased
plasma renin concentrations. Previous studies suggest that
amlodipine has biphasic effects on plasma renin activity in
rodents, with reductions at low doses and stimulation of renin
at higher doses [55]. The basis for amlodipine exerting these
effects on plasma renin concentrations has not been defined.
In our experience, plasma renin concentrations in mice are
inversely related to plasma concentrations of AngII [24,56,57],
as also demonstrated in the present study by pronounced
reductions in plasma renin concentrations in AngII-infused
Figure 3.  Amlodipine ablated AngII-induced abdominal aortic aneurysms.  Ex vivo suprarenal aortic diameter was measured
after termination. Circles and triangles are individual measurements, diamonds means of the groups, and error bars SEMs.
Representative images of aortas are shown below the graph. Statistical analyses were performed using nonparametric Kruskal-
Wallis test. * denotes P=0.0006 for comparison between AngII + vehicle and saline + vehicle, and # denotes P=0.003 for comparison
between AngII + amlodipine and AngII + vehicle groups.
doi: 10.1371/journal.pone.0081743.g003
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mice. Therefore, the observed elevations in plasma renin
concentration by amlodipine suggest a reduction in
endogenous production of AngII. This may have contributed to
the ability of amlodipine to reduce vascular pathologies.
Although both abdominal and ascending aortic aneurysms
are defined by pronounced aortic luminal expansion,
pathologies in these two locations are distinct [12,22,58-60]. In
AngII infused mice, abdominal aortic aneurysms appear to be
initiated by rapid medial macrophage accumulation co-localized
with focal elastin fragmentation, and these changes are
followed by rapid luminal expansion and marked leukocyte
infiltration in the adventitia [61,62]. In contrast, during the
initiation of AngII-induced ascending aortic aneurysms, one of
the earliest pathological changes is hemorrhage restricted to
the outer medial layers, and subsequent concentric medial
changes and luminal dilation, while leukocyte infiltration is not
as pronounced as in abdominal aortic aneurysms [60]. In spite
of significant differences of these two aortic aneurysms, the
present study demonstrated that amlodipine reduced aortic
expansion in both abdominal and ascending regions. In
agreement with our findings, a recent study reported that
amlodipine profoundly reduced incidence of abdominal and
thoracic aortic aneurysms in normocholesterolemic mice co-
administered either AngII or deoxycorticosterone acetate-salt
with a lysyl oxidase inhibitor, beta-aminopropionitrile [54]. This
model creates profound dilation of a translucent aorta from the
middle of the ascending region to aortic orifice of the
subclavian arterial branch. Therefore, this pathology differs
from that formed during AngII infusion in which dilation is
restricted to the full length of the ascending aorta and the
media is thickened and opaque [12]. Despite differences in
gross appearance, amlodipine markedly decreased thoracic
aortic pathologies in both animal models. Currently, information
from humans with ascending aortic aneurysms is limited to a
small study inferring benefits in young patients with Marfan’s
syndrome who were administered a non-dihydropyridine
calcium channel blocker, verapamil [63].
Calcium channel blockade has also been studied in a rat
model of abdominal aortic aneurysms induced by intra-aortic
infusion of elastase. Two different members of the
dihydropyridine class of calcium channel blockers, azelnidipine
and nifedipine, reduced AAAs formed in this model [64,65]. In
contrast to these reports and what was found in the present
study, a retrospective investigation reported that calcium
channel blockade was associated with the presence of
abdominal aortic aneurysms. However, administration of
calcium channel blockers did not affect aortic dilation rate. The
authors acknowledged potential compounding factors in this
retrospective analysis and noted the need for prospective
studies [25]. Currently, two prospective studies are evaluating
Figure 4.  Amlodipine preserved normal aortic structure in the suprarenal and ascending regions.  Tissue sections from
AngII-infused mice also infused with amlodipine were immunostained with alpha actin and CD68 to detect smooth muscle cells and
macrophages, respectively. Positive reactivity is show by intense red color. Verhoeff’s hematoxylin staining was performed to
facilitate visualization of elastin.
doi: 10.1371/journal.pone.0081743.g004
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effects of amlodipine on growth of AAAs in humans
(NCT01425242 and NC01118520). Completion of these
studies will provide insight into the validity of translating results
from AngII-induced AAAs in mice to humans.
In contrast to the limited information on aortic aneurysms,
there have been many experimental and human studies to
determine effects of multiple calcium channel blockers on
atherosclerosis [66]. Several of these studies have investigated
effects of amlodipine in mouse atherosclerosis models with
either apoE deletion or mutation. These reports provided a
range of results with amlodipine reducing atherosclerotic lesion
size [41,42,46,67-69] or having no effect [43-45,70]. In the
present study, we used saturated fat-fed LDL receptor -/- mice
infused with AngII, and found that amlodipine decreased
atherosclerosis. The conflicting findings in the literature may be
partially explained by different doses of amlodipine used and
mode of drug delivery; however, potential mechanisms of the
conflicting findings remain to be unraveled.
The overt differences in the appearance of AngII-induced
abdominal aortic aneurysms, ascending aortic aneurysms, and
atherosclerosis imply that the octapeptide is stimulating several
mechanisms to produce these diverse pathologies. Therefore,
the profound effects of amlodipine on all these pathologies also
imply that the drug is potentially interfering with many
mechanisms. Amlodipine has been demonstrated to influence
many processes that have been invoked in AngII-induced
vascular pathologies include reductions in oxidant stress [41],
matrix metalloproteinases [71], nitric oxide synthesis [72], and
leukocyte migration [47]. However, the contribution of each of
these mechanisms to reducing AngII-induced vascular
pathologies remains to be determined.
In conclusion, administration of amlodipine was studied in a
mouse model that simultaneous developments aortic
aneurysms and atherosclerosis. Although several studies have
observed disparities in response to different AngII-induced
vascular pathologies, this study demonstrated that continuous
infusion of amlodipine, at a dose that achieved therapeutically
relevant plasma concentrations, markedly reduced all these
pathologies.
Figure 5.  Amlodipine attenuated AngII-induced ascending aortic aneurysms.  Ascending aortic areas were measured using
an en face method. Circles and triangles are individual measurements, diamonds are means of groups, and error bars are SEMs.
Representative images of aortas are shown below the graph. Statistical analyses were performed using nonparametric Kruskal-
Wallis test. * denotes P=0.001 for comparison between AngII + vehicle and saline + vehicle groups, and # denotes P=0.03 for
comparison between AngII + amlodipine and AngII + vehicle groups.
doi: 10.1371/journal.pone.0081743.g005
Amlodipine Attenuates Aortic Aneurysms
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e81743
Acknowledgements
We acknowledge Sunkara Manjula for mass spectrometry
measurements of plasma amlodipine, and Vicki English for
plasma renin measurements. We thank Dr. Hong Lu for
assistance in editing the manuscript.
Author Contributions
Conceived and designed the experiments: XC AD. Performed
the experiments: XC DR DAH AB JM. Analyzed the data: XC
DR DAH AB JM AJM RC LAC AD. Contributed reagents/
materials/analysis tools: AJM AD. Wrote the manuscript: XC
DR DAH AB JM AJM RC LAC AD.
References
1. Bengtsson H, Sonesson B, Bergqvist D (1996) Incidence and
prevalence of abdominal aortic aneurysms, estimated by necropsy
studies and population screening by ultrasound. Ann NY Acad Sci 800:
1-24. doi:10.1111/j.1749-6632.1996.tb33294.x. PubMed: 8958978.
2. Homme JL, Aubry MC, Edwards WD, Bagniewski SM, Shane Pankratz
V et al. (2006) Surgical pathology of the ascending aorta: a
clinicopathologic study of 513 cases. Am J Surg Pathol 30: 1159-1168.
PubMed: 16931961.
3. Duncan JL, Harrild KA, Iversen L, Lee AJ, Godden DJ (2012) Long
term outcomes in men screened for abdominal aortic aneurysm:
prospective cohort study. BMJ 344: e2958. doi:10.1136/bmj.e2958.
PubMed: 22563092.
4. Golledge J, Muller J, Daugherty A, Norman P (2006) Abdominal aortic
aneurysm. Pathogenesis and implications for management. Arterioscler
Thromb Vasc Biol 26: 2605-2613. doi:10.1161/01.ATV.
0000245819.32762.cb. PubMed: 16973970.
5. Alcorn HG, Wolfson SK Jr, Sutton-Tyrrell K, Kuller LH, O'Leary D
(1996) Risk factors for abdominal aortic aneurysms in older adults
enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc
Biol 16: 963-970. doi:10.1161/01.ATV.16.8.963. PubMed: 8696960.
6. Daugherty A, Lu H, Rateri DL, Cassis LA (2008) Augmentation of the
renin-angiotensin system by hypercholesterolemia promotes vascular
diseases. Future Lipidol 3: 625-636. doi:10.2217/17460875.3.6.625.
PubMed: 19802341.
7. Rader DJ, Daugherty A (2008) Translating molecular discoveries into
new therapies for atherosclerosis. Nature 451: 904-913. doi:10.1038/
nature06796. PubMed: 18288179.
8. Daugherty A, Cassis L (1999) Chronic angiotensin II infusion promotes
atherogenesis in low density lipoprotein receptor -/- mice. Ann NY Acad
Sci 892: 108-118. doi:10.1111/j.1749-6632.1999.tb07789.x. PubMed:
10842656.
9. Daugherty A, Manning MW, Cassis LA (2000) Angiotensin II promotes
atherosclerotic lesions and aneurysms in apolipoprotein E-deficient
mice. J Clin Invest 105: 1605-1612. doi:10.1172/JCI7818. PubMed:
10841519.
10. Deng GG, Martin-McNulty B, Sukovich DA, Freay A, Halks-Miller M et
al. (2003) Urokinase-type plasminogen activator plays a critical role in
angiotensin II-induced abdominal aortic aneurysm. Circ Res 92:
510-517. doi:10.1161/01.RES.0000061571.49375.E1. PubMed:
12600880.
11. Uchida HA , Poduri A, Subramanian V, Cassis LA, Daugherty A (2011)
Urokinase-type plasminogen activator deficiency in bone marrow-
derived cells augments rupture of angiotensin II-induced abdominal
aortic aneurysms. Arterioscler Thromb Vasc Biol 31: 2845-2852. doi:
10.1161/ATVBAHA.111.234997. PubMed: 21868698.
12. Daugherty A, Rateri DL, Charo IF, Owens AP, Howatt DA et al. (2010)
Angiotensin II infusion promotes ascending aortic aneurysms:
Figure 6.  Amlodipine reduced AngII-induced atherosclerosis.  Percent atherosclerotic lesion area of thoracic aortas were
measured by an en face method. Circles and triangles are individual measurements, diamonds are means of the groups, and error
bars are SEMs. Statistical analyses were performed using nonparametric Kruskal-Wallis test. * denotes P=0.02 for comparison
between AngII + vehicle and saline + vehicle groups, and # denotes P=0.05 for comparison between AngII + amlodipine and AngII +
vehicle groups.
doi: 10.1371/journal.pone.0081743.g006
Amlodipine Attenuates Aortic Aneurysms
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e81743
attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) 118:
681-689. doi:10.1042/CS20090372.
13. Rateri DL, Moorleghen JJ, Knight V, Balakrishnan A, Howatt DA et al.
(2012) Depletion of endothelial or smooth muscle cell-specific
angiotensin II type 1a receptors does not influence aortic aneurysms or
atherosclerosis in LDL receptor deficient mice. PLOS ONE 7: e51483.
doi:10.1371/journal.pone.0051483. PubMed: 23236507.
14. Weiss D, Kools JJ, Taylor WR (2001) Angiotensin II-induced
hypertension accelerates the development of atherosclerosis in apoE-
deficient mice. Circulation 103: 448-454. doi:10.1161/01.CIR.
103.3.448. PubMed: 11157699.
15. Manning MW, Cassis LA, Daugherty A (2003) Differential effects of
doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on
angiotensin II-induced atherosclerosis and abdominal aortic
aneurysms. Arterioscler Thromb Vasc Biol 23: 483-488. doi:
10.1161/01.ATV.0000058404.92759.32. PubMed: 12615694.
16. Suen RS, Rampersad SN, Stewart DJ, Courtman DW (2011)
Differential Roles of Endothelin-1 in Angiotensin II-Induced
Atherosclerosis and Aortic Aneurysms in Apolipoprotein E-Null Mice.
Am J Pathol 179: 1549-1559. doi:10.1016/j.ajpath.2011.05.014.
PubMed: 21718678.
17. Subramanian V, Golledge J, Ijaz T, Bruemmer D, Daugherty A (2010)
Pioglitazone-induced reductions in atherosclerosis occur via smooth
muscle cell-specific interaction with PPAR{gamma}. Circ Res 107:
953-958. doi:10.1161/CIRCRESAHA.110.219089. PubMed: 20798360.
18. Henriques TA, Huang J, D'Souza SS, Daugherty A, Cassis LA (2004)
Orchidectomy, but not ovariectomy, regulates angiotensin II-induced
vascular diseases in apolipoprotein E-deficient mice. Endocrinology
145: 3866-3872. doi:10.1210/en.2003-1615. PubMed: 15105380.
19. King VL, Lin AY, Kristo F, Anderson TJ, Ahluwalia N et al. (2009)
Interferon-gamma and the interferon-inducible chemokine CXCL10
protect against aneurysm formation and rupture. Circulation 119:
426-435. doi:10.1161/CIRCULATIONAHA.108.785949. PubMed:
19139386.
20. Wang S, Subramanian V, Lu H, Howatt DA, Moorleghen JJ et al.
(2012) Deficiency of receptor-associated protein attenuates angiotensin
II-induced atherosclerosis in hypercholesterolemic mice without
influencing abdominal aortic aneurysms. Atherosclerosis 220: 375-380.
doi:10.1016/j.atherosclerosis.2011.11.013. PubMed: 22153700.
21. Uchida HA , Kristo F, Rateri DL, Lu H, Charnigo R et al. (2010) Total
lymphocyte deficiency attenuates AngII-induced atherosclerosis in
males but not abdominal aortic aneurysms in apoE deficient mice.
Atherosclerosis 211: 399-403. doi:10.1016/j.atherosclerosis.
2010.02.034. PubMed: 20362292.
22. Rateri DL, Moorleghen JJ, Balakrishnan A, Owens AP 3rd, Howatt DA
et al. (2011) Endothelial cell-specific deficiency of Ang II type 1a
receptors attenuates Ang II-induced ascending aortic aneurysms in
LDL receptor-/- mice. Circ Res 108: 574-581. doi:10.1161/
CIRCRESAHA.110.222844. PubMed: 21252156.
23. Daugherty A, Manning MW, Cassis LA (2001) Antagonism of AT2
receptors augments angiotensin II-induced abdominal aortic aneurysms
and atherosclerosis. Br J Pharmacol 134: 865-870. doi:10.1038/sj.bjp.
0704331. PubMed: 11606327.
24. Cassis LA, Rateri DL, Lu H, Daugherty A (2007) Bone marrow
transplantation reveals that recipient AT1a receptors are required to
initiate angiotensin II-induced atherosclerosis and aneurysms.
Arterioscler Thromb Vasc Biol 27: 380-386. PubMed: 17158350.
25. Wilmink AB, Vardulaki KA, Hubbard CS, Day NE, Ashton HA et al.
(2002) Are antihypertensive drugs associated with abdominal aortic
aneurysms? J Vasc Surg 36: 751-757. doi:10.1016/
S0741-5214(02)00129-5. PubMed: 12368736.
26. Lichtlen PR, Hugenholtz PG, Raffenbeul W, Hecker H, Jost S et al.
(1990) Retardation of angiographic progression of coronary artery
disease by nifedipine: Results of International nifedipine Trial on
Antiatherosclerotic therapy (INTACT). Lancet 1: 1109-1113.
27. Waters D, Lespérance J, Frncetish M, Causey D, Théroux P et al.
(1990) A controlled clinical trial to assess the effect of a calcium
channel blocker on the progression of coronary atherosclerosis.
Circulation 82: 1940-1953. doi:10.1161/01.CIR.82.6.1940. PubMed:
2242520.
28. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G et al. (2002)
Calcium antagonist lacidipine slows down progression of asymptomatic
carotid atherosclerosis: principal results of the European Lacidipine
Study on Atherosclerosis (ELSA), a randomized, double-blind, long-
term trial. Circulation 106: 2422-2427. doi:10.1161/01.CIR.
0000039288.86470.DD. PubMed: 12417537.
29. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ et al.
(2000) Effect of amlodipine on the progression of atherosclerosis and
the occurrence of clinical events. Circulation 102: 1503-1510. doi:
10.1161/01.CIR.102.13.1503. PubMed: 11004140.
30. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M et al. (2004)
Effect of antihypertensive agents on cardiovascular events in patients
with coronary disease and normal blood pressure: the CAMELOT
study: a randomized controlled trial. JAMA 292: 2217-2225. doi:
10.1001/jama.292.18.2217. PubMed: 15536108.
31. Daugherty A, Rateri D, Lu H, Balakrishnan A (2009) Measuring blood
pressure in mice using volume pressure recording, a tail-cuff method. J
Vis Exp 1291: ([MedlinePgn:]) PubMed: 19488026.
32. Daugherty A, Rateri DL (1994) Presence of LDL receptor-related
protein/alpha 2-macroglobulin receptors in macrophages of
atherosclerotic lesions from cholesterol- fed New Zealand and
heterozygous Watanabe heritable hyperlipidemic rabbits. Arterioscler
Thromb 14: 2017-2024. doi:10.1161/01.ATV.14.12.2017. PubMed:
7526898.
33. Bhatt J, Shah B, Kambli S, Subbaiah G, Singh S et al. (2007) Rapid
and sensitive method for the determination of sibutramine active
metabolites in human plasma by reversed-phase liquid
chromatography-tandem mass spectroscopy. J Chromatogr Sci 45:
91-96. doi:10.1093/chromsci/45.2.91. PubMed: 17425138.
34. Cassis LA (1992) Downregulation of the renin-angiotensin system in
streptozotocin-diabetic rats. Am J Physiol, 262: E105-E109. PubMed:
1733240.
35. Owens AP 3rd, Rateri DL, Howatt DA, Moore KJ, Tobias PS et al.
(2011) MyD88 deficiency attenuates angiotensin II-induced abdominal
aortic aneurysm formation independent of signaling through toll-like
receptors 2 and 4. Arterioscler Thromb Vasc Biol 31: 2813-2819. doi:
10.1161/ATVBAHA.111.238642. PubMed: 21960563.
36. Daugherty A, Whitman SC (2003) Quantification of atherosclerosis in
mice. Methods Mol Biol 209: 293-309. PubMed: 12357958.
37. Daugherty A, Rateri DL (2005) Development of experimental designs
for atherosclerosis studies in mice. Methods 36: 129-138. doi:10.1016/
j.ymeth.2004.11.008. PubMed: 15893934.
38. Lu H, Rateri DL, Daugherty A (2007) Immunostaining of mouse
atherosclerosis lesions. Methods Mol Med 139: 77-94. doi:
10.1007/978-1-59745-571-8_4. PubMed: 18287665.
39. Findeisen HM, Gizard F, Zhao Y, Cohn D, Heywood EB et al. (2011)
Telomerase deficiency in bone marrow-derived cells attenuates
angiotensin II-induced abdominal aortic aneurysm formation.
Arterioscler Thromb Vasc Biol 31: 253-260. doi:10.1161/ATVBAHA.
110.218545. PubMed: 21088250.
40. Rateri DL, Howatt DA, Moorleghen JJ, Charnigo R, Cassis LA et al.
(2011) Prolonged infusion of angiotensin II in apoE(-/-) mice promotes
macrophage recruitment with continued expansion of abdominal aortic
aneurysm. Am J Pathol 179: 1542-1548. doi:10.1016/j.ajpath.
2011.05.049. PubMed: 21763672.
41. Yoshii T, Iwai M, Li Z, Chen R, Ide A et al. (2006) Regression of
atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative
stress actions. Hypertens Res 29: 457-466. doi:10.1291/hypres.29.457.
PubMed: 16940709.
42. Trion A, de Maat M, Jukema W, Maas A, Offerman E et al. (2006) Anti-
atherosclerotic effect of amlodipine, alone and in combination with
atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. J Cardiovasc
Pharmacol 47: 89-95. doi:10.1097/01.fjc.0000195603.65858.27.
PubMed: 16424791.
43. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V et al. (2004)
Irbesartan but not amlodipine suppresses diabetes-associated
atherosclerosis. Circulation 109: 1536-1542. doi:10.1161/01.CIR.
0000124061.78478.94. PubMed: 15023892.
44. Delsing DJM, Jukema JW, van de Wiel MA, Emeis JJ, van der Laarse
A et al. (2003) Differential effects of amlodipine and atorvastatin
treatment and their combination on atherosclerosis in ApoE*3-Leiden
transgenic mice. J Cardiovasc Pharmacol 42: 63-70. doi:
10.1097/00005344-200307000-00010. PubMed: 12827028.
45. Doran DE, Weiss D, Zhang Y, Griendling KK, Taylor WR (2007)
Differential effects of AT(1) receptor and Ca(2+) channel blockade on
atherosclerosis, inflammatory gene expression, and production of
reactive oxygen species. Atherosclerosis 195: 39-47. doi:10.1016/
j.atherosclerosis.2007.02.018. PubMed: 17224157.
46. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D et al.
(2008) Renin inhibition by aliskiren prevents atherosclerosis
progression: comparison with irbesartan, atenolol, and amlodipine.
Hypertension 51: 1306-1311. doi:10.1161/HYPERTENSIONAHA.
108.110932. PubMed: 18391092.
47. Das R, Burke T, Van Wagoner DR, Plow EF (2009) L-type calcium
channel blockers exert an antiinflammatory effect by suppressing
expression of plasminogen receptors on macrophages. Circ Res 105:
167-175. doi:10.1161/CIRCRESAHA.109.200311. PubMed: 19520970.
Amlodipine Attenuates Aortic Aneurysms
PLOS ONE | www.plosone.org 9 November 2013 | Volume 8 | Issue 11 | e81743
48. Jeppesen P, Bruun J, Nielsen-Kudsk F (1998) Amlodipine dynamic
effects and myocardial pharmacokinetics in the isolated and perfused
guinea-pig heart. Pharmacol Toxicol 82: 250-256. doi:10.1111/j.
1600-0773.1998.tb01433.x. PubMed: 9646331.
49. Noguchi K , Takahashi K, Higuchi S (1998) In-vitro negative
chronotropic and inotropic effects of a novel dihydropyridine derivative,
CD-832, in the guinea-pig: comparison with calcium-channel
antagonists. J Pharm Pharmacol 50: 329-334. doi:10.1111/j.
2042-7158.1998.tb06869.x. PubMed: 9600727.
50. Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW (1986)
The pharmacokinetics of amlodipine in healthy volunteers after single
intravenous and after 14 repeated oral doses given once daily. Br J Clin
Pharmacol 22: 21-25. doi:10.1111/j.1365-2125.1986.tb02874.x.
PubMed: 2943308.
51. Bhatt J, Singh S, Subbaiah G, Shah B, Kambli S et al. (2007) A rapid
and sensitive liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method for the estimation of amlodipine in human plasma 21.
Chromatogr: Biomed. pp. 169-175.
52. Cassis LA, Gupte M, Thayer S, Zhang X, Charnigo R et al. (2009)
Angiotensin II infusion promotes abdominal aortic aneurysms
independent of increased blood pressure in hypercholesterolemic mice.
Am J Physiol Heart Circ Physiol 296: H1660-H1665. doi:10.1152/
ajpheart.00028.2009. PubMed: 19252100.
53. Lu H, Cassis LA, Daugherty A (2007) Atherosclerosis and arterial blood
pressure in mice. Curr Drug Targets 8: 1181-1189. doi:
10.2174/138945007782403829. PubMed: 18045096.
54. Kanematsu Y, Kanematsu M, Kurihara C, Tsou TL, Nuki Y et al. (2010)
Pharmacologically induced thoracic and abdominal aortic aneurysms in
mice. Hypertension 55: 1267-1274. doi:10.1161/HYPERTENSIONAHA.
109.140558. PubMed: 20212272.
55. Schricker K, Hamann M, Macher A, Krämer BK, Kaissling B et al.
(1996) Effect of amlodipine on renin secretion and renin gene
expression in rats. Br J Pharmacol 119: 744-750. doi:10.1111/j.
1476-5381.1996.tb15735.x. PubMed: 8904650.
56. Lu H, Balakrishnan A, Howatt DA, Wu C, Charnigo R et al. (2012)
Comparative effects of different modes of renin angiotensin system
inhibition on hypercholesterolaemia-induced atherosclerosis. Br J
Pharmacol 165: 2000-2008. doi:10.1111/j.1476-5381.2011.01712.x.
PubMed: 22014125.
57. Lu H, Rateri DL, Feldman DL, Charnigo RJ Jr, Fukamizu A et al. (2008)
Renin inhibition reduces hypercholesterolemia-induced atherosclerosis
in mice. J Clin Invest 118: 984-993. PubMed: 18274671.
58. Daugherty A, Cassis LA, Lu H (2011) Complex pathologies of
angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci
B 12: 624-628. doi:10.1631/jzus.B1101002. PubMed: 21796801.
59. Bruemmer D, Daugherty A, Lu H, Rateri DL (2011) Relevance of
angiotensin II-induced aortic pathologies in mice to human aortic
aneurysms. Ann N Y Acad Sci 1245: 7-10. doi:10.1111/j.
1749-6632.2011.06332.x. PubMed: 22211965.
60. Lu H, Rateri DL, Bruemmer D, Cassis LA, Daugherty A (2012)
Involvement of the renin-angiotensin system in abdominal and thoracic
aortic aneurysms. Clin Sci 123: 531-543. doi:10.1042/CS20120097.
PubMed: 22788237.
61. Saraff K, Babamusta F, Cassis LA, Daugherty A (2003) Aortic
dissection precedes formation of aneurysms and atherosclerosis in
angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler
Thromb Vasc Biol 23: 1621-1626. doi:10.1161/01.ATV.
0000085631.76095.64. PubMed: 12855482.
62. Barisione C, Charnigo R, Howatt DA, Moorleghen JJ, Rateri DL et al.
(2006) Rapid dilation of the abdominal aorta during infusion of
angiotensin II detected by noninvasive high-frequency ultrasonography.
J Vasc Surg 44: 372-376. doi:10.1016/j.jvs.2006.04.047. PubMed:
16890871.
63. Rossi-Foulkes R, Roman MJ, Rosen SE, Kramer-Fox R, Ehlers KH et
al. (1999) Phenotypic features and impact of beta blocker or calcium
antagonist therapy on aortic lumen size in the Marfan syndrome. Am J
Cardiol 83: 1364-1368. doi:10.1016/S0002-9149(99)00101-0. PubMed:
10235096.
64. Yokokura H, Hiromatsu S, Akashi H, Kato S , Aoyagi S (2007) Effects
of calcium channel blocker azelnidipine on experimental abdominal
aortic aneurysms. Surg Today 37: 468-473. doi:10.1007/
s00595-006-3367-6. PubMed: 17522763.
65. Tomita N, Yamasaki K, Izawa K, Kunugiza Y, Osako MK et al. (2008)
Inhibition of experimental abdominal aortic aneurysm progression by
nifedipine. Int J Mol Med 21: 239-244. PubMed: 18204791.
66. Mancini GB (2002) Antiatherosclerotic effects of calcium channel
blockers. Prog Cardiovasc Dis 45: 1-20. doi:10.1016/
S0033-0620(02)70007-8. PubMed: 12138411.
67. Weiss D, Taylor WR (2008) Deoxycorticosterone acetate salt
hypertension in apolipoprotein E-/- mice results in accelerated
atherosclerosis: the role of angiotensin II. Hypertension 51: 218-224.
doi:10.1161/HYPERTENSIONAHA.107.095885. PubMed: 18158357.
68. van de Poll SW, Delsing DJ, Jukema JW, Princen HM , Havekes LM et
al. (2002) Raman spectroscopic investigation of atorvastatin,
amlodipine, and both on atherosclerotic plaque development in
APOE*3 Leiden transgenic mice. Atherosclerosis 164: 65-71. doi:
10.1016/S0021-9150(02)00055-2. PubMed: 12119194.
69. van de Poll SW, Delsing DJ, Wouter Jukema J, Princen HM, Havekes
LM et al. (2003) Effects of amlodipine, atorvastatin and combination of
both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic
mice. J Mol Cell Cardiol 35: 109-118. doi:10.1016/
S0022-2828(02)00284-5. PubMed: 12623305.
70. Nakandakare ER, Charf AM, Santos FC, Nunes VS, Ortega K et al.
(2008) Dietary salt restriction increases plasma lipoprotein and
inflammatory marker concentrations in hypertensive patients.
Atherosclerosis 200: 410-416. doi:10.1016/j.atherosclerosis.
2007.12.034. PubMed: 18262533.
71. Yue H, Uzui H, Shimizu H, Nakano A, Mitsuke Y et al. (2004 ) Different
effects of calcium channel blockers on matrix metalloproteinase-2
expression in cultured rat cardiac fibroblasts. J Cardiovasc Pharmacol
44: 223-230. doi:10.1097/00005344-200408000-00012. PubMed:
15243304.
72. Kataoka C, Egashira K, Ishibashi M, Inoue S, Ni W et al. (2004) Novel
anti-inflammatory actions of amlodipine in a rat model of
arteriosclerosis induced by long-term inhibition of nitric oxide synthesis.
Am J Physiol Heart Circ Physiol 286: H768-H774. doi:10.1152/ajpheart.
00937.2002. PubMed: 14592942.
Amlodipine Attenuates Aortic Aneurysms
PLOS ONE | www.plosone.org 10 November 2013 | Volume 8 | Issue 11 | e81743
